Valganciclovir to Reduce T Cell Activation in HIV Infection
| Status: | Archived |
|---|---|
| Conditions: | HIV / AIDS, Hospital |
| Therapuetic Areas: | Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
The purpose of this study is to determine whether treatment with valganciclovir decreases T
cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV)
co-infection, potentially improving immune responses to antiretroviral therapy.
We found this trial at
1
site
San Francisco General Hospital San Francisco General Hospital and Trauma Center (SFGH) is an essential...
Click here to add this to my saved trials
